Phase III Randomized Study of Imatinib therapy in chornic phase chronic myeloid leukemia comparing standard dose-escalation with progressive dose-escalation (JALSG CML207study)

Authors
Category Primary study
JournalUMIN Clinical Trials Registry
Year 2007
INTERVENTION: imatinib imatinib CONDITION: Previously untreated Chronic‐phase chronic myelogenous leukemia PRIMARY OUTCOME: Molecular response at 12 months of imatinib therapy SECONDARY OUTCOME: 1 Overall survival at three years; 2 Cytogenetic response at 2 years; 3 Adverse events grade 3 and more INCLUSION CRITERIA: 1. Previously untreated chronic phase CML 2. Age: 15=< <70 3. PS 0‐3 (ECOG) 4. No severe major organ dysfunction 5. Written informed consent
Epistemonikos ID: 8853b83babc260e7ed47d890a572f02e0a7dcbf6
First added on: Aug 21, 2024